HomocystinuriaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

618 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp49

Immediate priorities

›Acute thromboembolic emergency

›Ischemic stroke presentation

›Acute neurologic deficit with tHcy >100 µmol/L

›Activate stroke protocol; imaging within 25 minutes

›Avoid dehydration; IV normal saline at maintenance rate

›Pulmonary embolism presentation

›Dyspnea, pleuritic chest pain, hypoxemia

›CT pulmonary angiography if hemodynamically stable

›Anticoagulation per hematology guidance

›Cerebral venous sinus thrombosis

›Headache, papilledema, focal deficit, or seizure in known HCU

›MR venography or CT venography urgently

›Anticoagulation typically indicated

›Airway and hemodynamic stabilization

›If altered mental status or GCS <13, immediate airway assessment

›Avoid nitrous oxide induction agents

›Metabolic specialist contact prior to anesthesia if possible

›Hemodynamic targets

›MAP >65 mmHg

›SpO2 >94% on supplemental oxygen

Monitoring and targets

›Monitoring bundle

›Continuous pulse oximetry and cardiac monitoring

›Tachyarrhythmia may indicate PE or ischemia

›Metabolic targets on treatment

›tHcy target <50 µmol/L for B6-responsive patients

›tHcy target <100 µmol/L for B6-nonresponsive patients

02History/hx56

Presentation pattern

›Ophthalmic symptoms

›Progressive myopia in childhood

›Often first presenting symptom in unscreened patients

›Sudden blurred vision or monocular visual loss

›Acute lens dislocation until proven otherwise

›Photophobia, floaters

›Thromboembolic symptoms

›Limb swelling, pain, redness

›DVT; may be recurrent

›Chest pain and dyspnea

›PE; may coexist with DVT

›Focal neurologic deficit, speech changes, weakness

›Ischemic stroke; ~one-third of thromboembolic events are cerebrovascular

›Severe headache, vomiting, visual changes

›Cerebral venous sinus thrombosis

›Neuropsychiatric symptoms

›Developmental delay or intellectual disability

›Present in ~50% of untreated B6-nonresponsive patients

›Seizures; dystonia; movement disorder

›Behavioral changes, anxiety, psychosis, hallucinations

›Musculoskeletal symptoms

›Tall stature, long limbs, scoliosis, pectus deformity

›Bone pain, fractures

›Osteoporosis common in untreated and poorly controlled patients

Risk factors

›Genetic and metabolic risk

›Autosomal recessive inheritance; parental consanguinity

03Physical Exam/exam43

General appearance and habitus

›Marfanoid habitus

›Tall, thin build; dolichostenomelia (disproportionately long limbs)

›Arachnodactyly (positive thumb sign, positive wrist sign)

›Pectus excavatum or carinatum

›High-arched palate; retrognathia

›No joint hypermobility (distinguishes HCU from Marfan syndrome)

›Joint laxity absent in homocystinuria; hypermobility present in Marfan

›Skin and hair findings

›Hypopigmentation of skin and hair (fair complexion, light hair)

›Malar flush

›Livedo reticularis on extremities

Ophthalmologic examination

›Ocular signs

›Iridodonesis (trembling of iris with eye movement)

›Sign of posterior lens subluxation; pathognomonic clue

›Ectopia lentis

›Typically inferonasal or downward displacement in HCU

›Upward displacement in Marfan syndrome (distinguishing feature)

›High myopia on fundoscopy or refraction testing

›Slit-lamp examination for lens position

Skeletal and neurologic examination

›Skeletal findings

›Scoliosis or kyphosis

›Genu valgum, pes cavus

›Reduced bone density on DXA (not clinically detectable; imaging required)

›Neurologic findings

›Focal neurologic deficits (stroke)

04Differential Diagnosis/ddx29

Connective tissue and skeletal mimics

›Marfan syndrome

›ICD-10: Q87.40

›Shares: marfanoid habitus, ectopia lentis, arachnodactyly

›Distinguishing: joint hypermobility present; lens dislocates upward; normal tHcy and methionine

›Ehlers-Danlos syndrome

›ICD-10: Q79.6

›Joint hypermobility prominent; skin hyperextensibility; no lens dislocation

›Stickler syndrome

›Myopia, vitreoretinal degeneration; normal homocysteine

Homocysteine-elevating metabolic disorders

›MTHFR deficiency (remethylation defect)

›ICD-10: E72.11

›Elevated tHcy but low (not elevated) methionine

›May have megaloblastic anemia; seizures; cognitive decline

›Cobalamin metabolism defects (CblC, CblD)

›ICD-10: E53.8

›Elevated tHcy plus methylmalonic acidemia; macrocytic anemia; low methionine

›Methionine adenosyltransferase (MAT I/III) deficiency

›ICD-10: E72.19

›Elevated methionine with normal or mildly elevated homocysteine

Acquired hyperhomocysteinemia

›Nutritional B12, B6, or folate deficiency

›ICD-10: E53.8, E53.1, E53.0

›tHcy typically 15–100 µmol/L; responds to supplementation

›Must be excluded before initiating HCU-specific treatment

›Renal insufficiency

›Impaired homocysteine clearance; tHcy mildly to moderately elevated

05Laboratory Tests/lt57

Primary metabolic tests

›Plasma total homocysteine (tHcy)

›Markedly elevated in CBS deficiency; often >100 µmol/L

›Normal reference <15 µmol/L

›Must be measured after 2-week washout of B6 supplementation for accuracy

›Mild-moderate elevation 15–100 µmol/L may indicate remethylation defects or acquired deficiency

›Plasma amino acid profile

›Elevated methionine (distinguishes CBS deficiency from remethylation defects)

›Methionine high or normal in CBS deficiency

›Methionine low in MTHFR and cobalamin defects

›Low cystathionine

›Elevated methionine-to-cystathionine ratio

›Urine organic acids / urine methylmalonic acid

›Elevated methylmalonic acid in cobalamin defects

›Normal in CBS deficiency and MTHFR deficiency

Cofactor and nutritional status

›Serum B12 (cobalamin)

›Low B12 can cause acquired hyperhomocysteinemia mimicking HCU

›Required before and during treatment monitoring

›RBC folate and serum folate

›Low RBC folate warrants folic acid 5 mg/day supplementation

›Serum pyridoxal-5-phosphate (B6)

›Guides pyridoxine dosing; baseline before challenge test

Treatment monitoring panel

›Ongoing monitoring labs

›Plasma tHcy (quarterly to annually per specialist)

›Target <50 µmol/L for B6-responsive patients

›Target <100 µmol/L for B6-nonresponsive patients

06Diagnostic Tests/dt64

Scoring Systems

›Pyridoxine responsiveness classification

›B6-responsive (~40% of patients)

›tHcy normalizes to <50 µmol/L on pyridoxine 200 mg/day

›Associated with milder phenotype and later complication onset

›B6-partial responders

›Partial reduction in tHcy with pyridoxine alone

›Combination therapy required

›B6-nonresponsive (~60% of patients)

›No significant tHcy reduction on pyridoxine

›Requires dietary restriction plus betaine; most severe phenotype

›Phenotype severity stratification

›Untreated natural history

›Ectopia lentis by age 8 in most untreated B6-nonresponsive patients

›~50% untreated patients have thromboembolic event by age 30

›~one-third of events are cerebrovascular

›Early treatment impact

›Thromboembolism risk ratio 0.073 in treated vs untreated (NBS cohort)

›Lens dislocation risk ratio 0.069 in treated vs untreated

MRI

›Brain MRI indications

›Suspected ischemic stroke or cerebral venous sinus thrombosis

›DWI sequence for early ischemia detection

›FLAIR sequence for subacute and chronic infarcts

›MR venography (MRV)

›Preferred for suspected CVST in patients without contraindication to MRI

›Superior soft tissue detail vs CT venography

›Betaine-associated cerebral edema

07Disposition/dispo29

Admission indications

›Mandatory admission criteria

›Acute ischemic stroke or hemorrhagic stroke

›Stroke unit admission; thrombolysis decision per neurology

›Acute pulmonary embolism

›Risk-stratify; intermediate- or high-risk PE requires monitored bed

›DVT with high clot burden or suspected iliofemoral DVT

›Cerebral venous sinus thrombosis

›Acute lens dislocation requiring surgical intervention

›NPO; ophthalmology admission or transfer

›Altered mental status or suspected cerebral edema from betaine therapy

›Metabolic decompensation during febrile illness with inability to tolerate oral intake

›IV hydration and metabolic monitoring required

Discharge criteria

›Safe discharge parameters

›Hemodynamically stable with no acute thrombosis or vision threat

›Tolerating oral metabolic medications and diet

›Pyridoxine responsiveness known or metabolic specialist contacted

›Clear follow-up arranged within 1–2 weeks with metabolic genetics

›Return precautions understood and documented

Transfer criteria

›Transfer triggers

›Acute stroke requiring endovascular thrombectomy not available on-site

›Complex metabolic management requiring tertiary metabolic center

›Lens dislocation requiring specialized ophthalmic surgery

›Neonatal or pediatric HCU in setting without pediatric metabolic expertise

Follow-up planning

›Outpatient monitoring requirements

08Treatment/t93

Acute management (ED and hospital)

›Acute thromboembolic treatment

›Anticoagulation for DVT or PE

›Low-molecular-weight heparin (LMWH) initial therapy

›Enoxaparin 1 mg/kg subcutaneous every 12 hours

›Adjust for renal function (CrCl <30 ml/min use unfractionated heparin)

›Transition to warfarin (target INR 2.0–3.0) after acute phase

›Hematology guidance for indefinite anticoagulation in recurrent events

›Ischemic stroke management

›Standard acute stroke protocol (tPA if eligible within 4.5 hours)

›Aspirin 325 mg per stroke guidelines after hemorrhage excluded

›Avoid dehydration; maintain euvolemia

›Perioperative anticoagulation

›Metabolic and hematology guidance required prior to any surgery

›Low threshold for thromboprophylaxis with LMWH

›IV hydration

›Normal saline or balanced crystalloid

›Maintain urine output >0.5 ml/kg/hour

›Particularly critical during febrile illness, surgery, or prolonged fasting

Pyridoxine (vitamin B6) therapy

›Pyridoxine for B6-responsive patients

›Target tHcy <50 µmol/L

›Adult starting dose: 100–200 mg/day orally in divided doses

›Titrate to lowest dose achieving target; typical adult 2–5 mg/kg/day

›Maximum recommended dose: 500 mg/day

›Peripheral sensory neuropathy risk at doses >900 mg/day (avoid)

›Pediatric pyridoxine dosing

›Infants: 100 mg/day initial trial

›Children: 2–5 mg/kg/day; reassess response at 6 weeks

›B6 responsiveness assessment

›Perform pyridoxine challenge: measure tHcy before and 6 weeks after starting pyridoxine

›>50% reduction in tHcy with normalization is responsive

Betaine (trimethylglycine) therapy

›Betaine for B6-nonresponsive and partial responders

›Mechanism: remethylation of homocysteine to methionine via alternative pathway

›Adult dosing

›Starting dose: 3 g orally twice daily

›Titrate weekly based on plasma tHcy and methionine response

›Maximum dose: 6 g twice daily (some patients require higher doses)

›Pediatric betaine dosing

›Starting dose: 50 mg/kg orally twice daily

›Titrate weekly; target tHcy <100 µmol/L

›Critical monitoring on betaine therapy

›Plasma methionine must remain <1,000 µmol/L

›Hypermethioninemia >1,000 µmol/L causes cerebral edema

›If methionine exceeds threshold: reduce betaine dose immediately

›Monitor sarcosine level to confirm compliance (>5 µmol/L = adherent)

Dietary therapy

›Methionine-restricted diet

›Primary therapy for B6-nonresponsive patients

›Restricts natural protein intake (especially animal protein)

›Supplements with methionine-free amino acid formula

›Methionine-free amino acid formula

›Provides cysteine, tryptophan, and essential amino acids without methionine

›Required to prevent protein malnutrition

›Cysteine becomes conditionally essential (transsulfuration pathway blocked)

›Dietary target

›Plasma methionine typically <800 µmol/L while preventing protein deficiency

›Hydration counseling

›Minimum 2 L fluid daily in adults; weight-based in children

›Especially during illness, heat, travel, or perioperative period

Adjunctive nutritional therapy

›Folic acid

›Dose: 5 mg orally daily

›Indicated when RBC folate is low

›Supports remethylation pathway

›Hydroxocobalamin (B12)

›Dose: 1 mg intramuscular monthly

›Indicated when serum B12 is low

›Hydroxocobalamin preferred over cyanocobalamin

›Pyridoxal-5-phosphate (active B6)

›Alternative formulation for patients with pyridoxine absorption issues

›Vitamin D and calcium

›Bone protection in context of osteoporosis risk

›Target 25-OH vitamin D >50 nmol/L

Emerging and surgical therapies

›Emerging pharmacologic therapies

›Pegtibatinase (SYNT-202)

›Engineered CBS enzyme replacement; in phase 3 clinical trials

›Pharmacological chaperones targeting specific CBS mutations (investigational)

›Gene therapy approaches in preclinical development

›Liver transplantation

›Remains only definitive curative therapy for severe B6-nonresponsive HCU

›Corrects CBS enzyme deficiency in liver

›Reserved for cases with ongoing complications despite maximal therapy

›Ophthalmologic surgical interventions

›Lensectomy for dislocated lens causing visual impairment or glaucoma

›High perioperative thrombotic risk; optimize metabolic control preoperatively

›Avoid nitrous oxide during anesthesia

Contraindications and avoidances

›Medications and exposures to avoid

›Nitrous oxide (N2O)

›Irreversibly inactivates methionine synthase

›Acutely worsens homocysteine accumulation

›Contraindicated in all HCU patients (anesthesia team must be notified)

›Combined oral contraceptives

›Substantially increases thrombotic risk in affected females

›Progestin-only contraception preferred; consult hematology

›Dehydration and immobilization

›Major modifiable thrombotic risk triggers

09Special Populations/sp59

Pregnancy

›Maternal and fetal risks

›Pregnancy increases thrombotic risk significantly

›Postpartum period carries highest thrombotic risk

›Case reports of fatal thromboembolism in postpartum HCU

›Preeclampsia risk may be elevated due to endothelial dysfunction from hyperhomocysteinemia

›Neonatal HCU: maternal homocysteine does not cross placenta in significant amounts

›Medication considerations in pregnancy

›Pyridoxine: considered safe in pregnancy at therapeutic doses

›Continue throughout pregnancy in B6-responsive patients

›Betaine: limited safety data; generally continued given thrombotic risk of undertreated HCU

›Folic acid: 5 mg/day; critical in pregnancy for neural tube protection

›Hydroxocobalamin: safe in pregnancy

›Avoid oral contraceptives postpartum; use LMWH thromboprophylaxis

›LMWH thromboprophylaxis throughout pregnancy and for 6 weeks postpartum

›Consult hematology and metabolic genetics

›Dietary management in pregnancy

›Methionine-restricted diet requires careful adjustment to ensure adequate protein

›Higher protein requirements in pregnancy; dietitian input essential

›Adequate cysteine, tyrosine, and other conditionally essential amino acids

Geriatric

›Aging and complication burden

›Cumulative thromboembolism risk increases with age in undertreated patients

›Arterial disease and atherosclerosis accelerated by hyperhomocysteinemia

›Osteoporotic fracture risk compounded by age-related bone loss

›Cognitive decline may accelerate; multiple cerebrovascular events

›Medication considerations in older adults

›Pyridoxine neuropathy risk increases with duration and dose

›Monitor for peripheral neuropathy symptoms; nerve conduction studies if indicated

›Renal function decline reduces LMWH clearance

›Dose-adjust enoxaparin or switch to unfractionated heparin if CrCl <30 ml/min

›Polypharmacy interactions; B12 absorption reduced by PPI and metformin use

›Parenteral B12 preferred in elderly patients with gastric atrophy

›Falls and fracture management

›Increased fracture risk from both osteoporosis and anticoagulation

›Multidisciplinary falls assessment in ambulatory patients

Pediatrics

›Neonatal and newborn screening

›NBS detects elevated methionine via tandem mass spectrometry

›B6-responsive forms may be missed due to near-normal methionine at birth

›Second-tier plasma homocysteine measurement improves detection

›Confirmatory plasma amino acids and tHcy in all abnormal NBS screens

›CBS enzyme assay in fibroblasts or molecular CBS testing for confirmation

›Pediatric treatment initiation

›Early treatment (prior to 6 weeks of age from NBS) dramatically reduces complications

›Thromboembolism risk ratio 0.073 vs untreated controls

›Lens dislocation risk ratio 0.069 vs untreated controls

›Pyridoxine trial: 100 mg/day in infants; response assessed at 6 weeks

›Methionine-restricted diet initiated promptly in B6-nonresponsive infants

›Methionine-free amino acid infant formula as primary nutrition

›Breastfeeding may be continued in combination with formula to limit methionine

›Developmental monitoring

›Regular neurodevelopmental assessments

›Intellectual disability in ~50% of untreated B6-nonresponsive children

›Educational support and early intervention planning

›Ophthalmology at diagnosis and annually

›Ectopia lentis detectable from age 2–3 in untreated B6-nonresponsive patients

›Annual slit-lamp exam to guide surgical timing

›Dosing considerations in children

›Betaine: 50 mg/kg orally twice daily; titrate weekly

›Weight-based dosing requires frequent reassessment as child grows

›Pyridoxine: 2–5 mg/kg/day in children once responsiveness confirmed

10Background/b71

Epidemiology

›Prevalence and incidence

›Global prevalence approximately 1 in 200,000–300,000

›Higher in populations with high consanguinity rates

›Ireland has higher prevalence (approximately 1 in 30,000–65,000) due to founder effect

›Autosomal recessive inheritance; equal sex distribution

›CBS deficiency accounts for ~90% of classic homocystinuria cases

›Estimated 2,000–5,000 affected individuals in the United States

›Complication incidence in untreated patients

›Thromboembolic event by age 30: ~50% of untreated patients

›~one-third cerebrovascular (stroke, CVST)

›~one-third venous (DVT, PE)

›~one-third arterial peripheral or coronary

›Ectopia lentis: present in >90% of untreated patients by adulthood

›Intellectual disability: present in ~50% of untreated B6-nonresponsive patients

›Osteoporosis detectable radiologically in >50% of untreated patients by age 20

›Mortality

›Thromboembolism is the major cause of premature death

›Early diagnosis and treatment substantially reduces mortality

›No contemporary population-level mortality data available

Pathophysiology

›CBS enzyme and metabolic pathway

›CBS catalyzes condensation of homocysteine with serine to form cystathionine

›CBS deficiency blocks the transsulfuration pathway

›Results in accumulation of homocysteine and methionine (upstream)

›Deficiency of cystathionine and cysteine (downstream)

›CBS is a pyridoxal-5-phosphate (B6)-dependent enzyme

›B6-responsive mutations have residual enzyme activity enhanced by cofactor

›B6-nonresponsive mutations have absent or non-cofactor-dependent residual activity

›Homocysteine toxicity mechanisms

›Endothelial injury

›Homocysteine impairs endothelial NO synthesis and promotes oxidative stress

›Activates coagulation cascade; inhibits protein C activation

›Promotes platelet aggregation and thrombin generation

›Net result: prothrombotic state affecting both arteries and veins

›Connective tissue effects

›Homocysteine disrupts cross-linking of collagen and fibrillin

›Fibrillin disruption causes ectopia lentis and marfanoid skeletal features

›Collagen cross-link disruption contributes to osteoporosis

›Neurologic effects

›Direct neurotoxicity via NMDA receptor overactivation

›Microvascular thrombosis causing ischemic brain injury

›Impaired myelination and white matter development

›Genotype-phenotype correlation

›>150 pathogenic CBS mutations described

›I278T: residual enzyme activity; B6-responsive; milder phenotype; can present in adulthood

›G307S: no residual activity; B6-nonresponsive; severe childhood-onset phenotype

›Phenotype variability even within same genotype; modifier genes and environment contribute

Therapeutic Considerations

›Treatment target rationale

›Reducing tHcy below 50 µmol/L (B6-responsive) or 100 µmol/L (B6-nonresponsive)

›Correlated with reduced thromboembolism and lens dislocation rates

›Methionine ceiling of 1,000 µmol/L on betaine therapy

›Hypermethioninemia >1,000 µmol/L: reversible white matter lesions and cerebral edema

›Pyridoxine maximum dose 500 mg/day

›Above 900 mg/day: irreversible sensory neuropathy documented

›Evidence base for treatment

›Mudd et al. international survey (1985): established natural history and complication rates

›Yap et al. (2001): demonstrated that lowering tHcy reduces thromboembolism risk

›NBS treated-vs-untreated comparisons: thromboembolism RR 0.073; lens dislocation RR 0.069

›E-HOD registry (2025): first prospective European registry characterizing real-world treatment patterns

›Treatment response monitoring

›Plasma tHcy the primary efficacy biomarker

›Sarcosine >5 µmol/L confirms betaine adherence with 97% sensitivity and 95% specificity

›Dietary compliance monitored via plasma methionine and nutritional markers

›Unmet therapeutic needs

›B6-nonresponsive patients have limited options beyond dietary restriction and betaine

›Pegtibatinase (CBS enzyme replacement): phase 3 trials ongoing

›Gene therapy and mRNA-based approaches in preclinical development

›Liver transplantation: curative but associated with surgical risk and immunosuppression burden

›ICD-10 coding

›E72.11: Homocystinuria (CBS deficiency is primary code)

›E72.19: Other disorders of sulfur-bearing amino acid metabolism

›SNOMED CT: 54365001 (Homocystinuria)

11Patient Discharge Instructions/pdi35

copy discharge instructions

›Diagnosis and condition overview

›Homocystinuria is a rare inherited metabolic condition where a substance called homocysteine builds up in your blood

›This can cause blood clots, eye problems, bone problems, and in some cases developmental issues

›With careful treatment, most complications can be prevented

›Medications — take exactly as prescribed

›Pyridoxine (vitamin B6): take every day as directed; do not skip doses

›This helps lower homocysteine levels in patients whose body responds to B6

›Betaine (Cystadane): take with meals; dose adjustments must only be made by your metabolic doctor

›Too high a dose can cause a dangerous chemical called methionine to rise; do not self-adjust dose

›Folic acid and vitamin B12: take as directed; important for homocysteine metabolism

›Do not take any new medications, supplements, or herbal products without checking with your metabolic team

›Diet instructions

›Follow your low-methionine diet strictly; your dietitian will provide a specific meal plan

›Take your amino acid formula as prescribed; this replaces the protein you are restricting

›Drink plenty of fluids every day — at least 8 glasses of water

›Activity and prevention

›Avoid long periods of sitting or lying still without moving (blood clots can form)

›During long car rides or flights, stand and walk every 1–2 hours

›Move your legs frequently if you cannot walk

›If you are having surgery or a procedure, make sure the anesthesia team knows you have homocystinuria

›Nitrous oxide (laughing gas) must NOT be used; it is harmful to people with your condition

›Do not use birth control pills if you are female with homocystinuria (increases clot risk)

›Ask your doctor about safe contraception options

›When to return to emergency immediately

›Sudden weakness or numbness in arm or leg, face drooping, speech difficulty (stroke)

›Sudden severe headache unlike any before

›Sudden blurred vision or loss of vision in one eye (possible lens dislocation)

12References/r33

Guidelines and key sources

›Sacharow SJ, Levy HL. Homocystinuria due to Cystathionine Beta-Synthase Deficiency

›GeneReviews, NCBI Bookshelf, 2025

›Primary evidence source for clinical presentation, diagnosis, and management

›Morris AAM, Sokolova J, Pavlikova M, et al. Cystathionine Beta-Synthase Deficiency in the E-HOD Registry Part II: Dietary and Pharmacological Treatment

›Journal of Inherited Metabolic Disease, 2025

›European prospective registry; real-world treatment outcomes

›Walter JH, Jahnke N, Remmington T. Newborn Screening for Homocystinuria

›Cochrane Database of Systematic Reviews, 2015

›NBS evidence; treated vs untreated outcome comparisons

›Testai FD, Gorelick PB. Inherited Metabolic Disorders and Stroke Part 2: Homocystinuria, Organic Acidurias, and Urea Cycle Disorders

›Archives of Neurology (JAMA Neurology), 2010

›Stroke risk and management in HCU

›Mandel H, Brenner B, Berant M, et al. Coexistence of Hereditary Homocystinuria and Factor V Leiden — Effect on Thrombosis

›New England Journal of Medicine, 1996

›Landmark study on compounding thrombotic risk

›Kluijtmans LA, Boers GH, Kraus JP, et al. The Molecular Basis of Cystathionine Beta-Synthase Deficiency in Dutch Patients

›American Journal of Human Genetics, 1999

›Genotype-phenotype correlation; I278T and G307S mutation characterization

›Gerrard A, Dawson C. Homocystinuria Diagnosis and Management: It Is Not All Classical

›Journal of Clinical Pathology, 2022

›Practical management review; sarcosine compliance monitoring

›Kozich V, Majtan T. Molecular Basis of Phenotype Expression in Homocystinuria: Where Are We 30 Years Later?

›Journal of Inherited Metabolic Disease, 2024

›Current understanding of molecular mechanisms and emerging therapies

›Welch GN, Loscalzo J. Homocysteine and Atherothrombosis

›New England Journal of Medicine, 1998

›Foundational paper on vascular toxicity mechanisms of homocysteine

Learn More: Homocystinuria→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.